Drugs / QLF31907
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05150405 | Oct 2021 → Mar 2024 | cancer, non-Hodgkin lymphoma | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06394713 | Jun 2024 → Jun 2025 overdue | cancer | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05823246 | Apr → Oct 2023 | melanoma, urothelial carcinoma | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLF31907 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05150405 ↗ |
| Route | Intravenous | “Intravenous infusion once every two weeks.” NCT05823246 ↗ |